United Therapeutics Co. (NASDAQ:UTHR) Stake Lifted by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd boosted its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 300.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,693 shares of the biotechnology company's stock after acquiring an additional 2,021 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in United Therapeutics were worth $949,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC lifted its stake in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after purchasing an additional 18,313,424 shares in the last quarter. World Investment Advisors LLC acquired a new position in United Therapeutics during the third quarter valued at approximately $139,206,000. FMR LLC lifted its position in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock valued at $386,168,000 after buying an additional 314,004 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after buying an additional 189,967 shares during the period. Finally, AustralianSuper Pty Ltd raised its stake in shares of United Therapeutics by 577.1% in the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock valued at $66,962,000 after acquiring an additional 161,751 shares during the period. Hedge funds and other institutional investors own 94.08% of the company's stock.

Remove Ads

United Therapeutics Trading Down 1.0 %

NASDAQ UTHR traded down $3.13 during trading hours on Tuesday, reaching $316.73. 345,532 shares of the company traded hands, compared to its average volume of 446,533. The company has a 50 day moving average of $344.24 and a two-hundred day moving average of $356.84. The stock has a market capitalization of $14.22 billion, a PE ratio of 13.91, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period last year, the firm earned $4.36 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 80,255 shares of company stock worth $28,995,021. 11.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

UTHR has been the topic of a number of recent research reports. UBS Group boosted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.